Literature DB >> 21464243

Consumption patterns and in vitro resistance of Streptococcus pneumoniae to fluoroquinolones.

Steven Simoens1, Jan Verhaegen, Pascal van Bleyenbergh, Willy E Peetermans, Marc Decramer.   

Abstract

This article analyzes patterns of consumption of fluoroquinolones and documents the in vitro resistances of Streptococcus pneumoniae isolates to fluoroquinolones in the ambulatory care setting in Belgium over time. The volume of fluoroquinolone consumption has fallen consistently since 2003. Fluoroquinolones were used primarily for their registered indications (i.e., urinary tract infections and lower respiratory tract infections). The MIC distributions of moxifloxacin and levofloxacin in S. pneumoniae isolates remained stable during 2004 to 2009, and the level of resistance to moxifloxacin and levofloxacin was low (≤1%).

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21464243      PMCID: PMC3101429          DOI: 10.1128/AAC.00019-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  3 in total

1.  The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents.

Authors:  Michael R Jacobs; David Felmingham; Peter C Appelbaum; Reuben N Grüneberg
Journal:  J Antimicrob Chemother       Date:  2003-07-15       Impact factor: 5.790

2.  Quinolones in the treatment of uncomplicated urinary tract infections.

Authors:  R R Bailey
Journal:  Int J Antimicrob Agents       Date:  1992-12       Impact factor: 5.283

3.  Efficacy and safety of levofloxacin in the context of other contemporary fluoroquinolones: a review.

Authors:  Peter Ball
Journal:  Curr Ther Res Clin Exp       Date:  2003-11
  3 in total
  3 in total

1.  Antibiotic activity against naive and induced Streptococcus pneumoniae biofilms in an in vitro pharmacodynamic model.

Authors:  Nathalie M Vandevelde; Paul M Tulkens; Françoise Van Bambeke
Journal:  Antimicrob Agents Chemother       Date:  2013-12-16       Impact factor: 5.191

Review 2.  Biological and Epidemiological Features of Antibiotic-Resistant Streptococcus pneumoniae in Pre- and Post-Conjugate Vaccine Eras: a United States Perspective.

Authors:  Lindsay Kim; Lesley McGee; Sara Tomczyk; Bernard Beall
Journal:  Clin Microbiol Rev       Date:  2016-07       Impact factor: 26.132

3.  Risk factors and clinical significance of invasive infections caused by levofloxacin-resistant Streptococcus pneumoniae.

Authors:  M C Isea-Peña; J C Sanz-Moreno; J Esteban; R Fernández-Roblas; M L Fernández-Guerrero
Journal:  Infection       Date:  2013-05-25       Impact factor: 3.553

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.